Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.36 -2.9%	$18.72	$13.52 ▼ $35.25	$1.70B	2.22	2.43 million shs	1.90 million shs
CRSP CRISPR Therapeutics	$51.83 -2.3%	$55.74	$30.04 ▼ $71.13	$4.82B	1.8	2.60 million shs	1.59 million shs
EDIT Editas Medicine	$2.57 -3.0%	$2.67	$0.91 ▼ $4.12	$238.29M	2.19	1.73 million shs	1.15 million shs
NTLA Intellia Therapeutics	$11.35 -2.2%	$11.28	$5.90 ▼ $23.76	$1.25B	2.31	4.43 million shs	2.78 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-2.91%	-1.68%	-18.81%	+3.94%	-37.20%
CRSP CRISPR Therapeutics	-2.30%	-4.58%	-10.14%	+43.81%	+9.16%
EDIT Editas Medicine	-3.02%	-8.21%	+1.98%	+48.13%	-30.16%
NTLA Intellia Therapeutics	-2.16%	+7.89%	-7.95%	+62.37%	-49.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.2171 of 5 stars	3.5	0.0	0.0	2.9	2.5	0.6
CRSP CRISPR Therapeutics	3.6193 of 5 stars	4.2	3.0	0.0	2.3	3.3	0.6
EDIT Editas Medicine	4.1772 of 5 stars	3.1	4.0	4.3	1.9	2.5	0.6
NTLA Intellia Therapeutics	4.4924 of 5 stars	4.3	1.0	4.7	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.45	196.18% Upside
CRSP CRISPR Therapeutics	2.47	Hold	$71.60	38.14% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	98.44% Upside
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	155.97% Upside

Current Analyst Ratings Breakdown

Latest EDIT, BEAM, CRSP, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	CRSP CRISPR Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.05	N/A	N/A	$10.35 per share	1.58
CRSP CRISPR Therapeutics	$37.31M	126.35	N/A	N/A	$18.81 per share	2.76
EDIT Editas Medicine	$32.31M	7.15	N/A	N/A	$0.21 per share	12.24
NTLA Intellia Therapeutics	$57.88M	21.05	N/A	N/A	$6.66 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	11/6/2025 (Estimated)

Latest EDIT, BEAM, CRSP, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
CRSP CRISPR Therapeutics	N/A	16.61	16.61
EDIT Editas Medicine	N/A	2.77	2.77
NTLA Intellia Therapeutics	N/A	5.19	5.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
EDIT Editas Medicine	71.90%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
CRSP CRISPR Therapeutics	4.30%
EDIT Editas Medicine	2.10%
NTLA Intellia Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable

EDIT, BEAM, CRSP, and NTLA Headlines

Recent News About These Companies

Jump Financial LLC Purchases 141,172 Shares of Intellia Therapeutics, Inc. $NTLA

August 28 at 6:14 AM | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up After Insider Buying Activity

August 27 at 10:52 AM | marketbeat.com

Cathie Wood’s ARK Investment buys 191.7K shares of Intellia Therapeutics today

August 26, 2025 | msn.com

Vanguard Group Inc. Acquires 561,978 Shares of Intellia Therapeutics, Inc. $NTLA

August 26, 2025 | marketbeat.com

Cathie Wood’s ARK Investment buys 359K shares of Intellia Therapeutics today

August 25, 2025 | msn.com

Aptus Capital Advisors LLC Sells 50,196 Shares of Intellia Therapeutics, Inc. $NTLA

August 24, 2025 | marketbeat.com

William Chase Buys 100,000 Shares of Intellia Therapeutics (NASDAQ:NTLA) Stock

August 23, 2025 | insidertrades.com

Cathie Wood’s ARK Investment buys 150.6K shares of Intellia Therapeutics today

August 21, 2025 | msn.com

Cathie Wood’s ARK Investment buys 560.6K shares of Intellia Therapeutics today

August 19, 2025 | msn.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 19, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Vestmark Advisory Solutions Inc.

August 18, 2025 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Time to Buy?

August 16, 2025 | marketbeat.com

Chardan Capital Has Strong Forecast for NTLA FY2025 Earnings

August 16, 2025 | marketbeat.com

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

August 15, 2025 | seekingalpha.com

Chardan Capital Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

August 12, 2025 | marketbeat.com

NTLA FY2027 EPS Increased by Brookline Capital Management

August 12, 2025 | marketbeat.com

Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results

August 11, 2025 | finance.yahoo.com

Wedbush Expects Reduced Earnings for Intellia Therapeutics

August 11, 2025 | marketbeat.com

Royal Bank Of Canada Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

August 10, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 7.3% on Analyst Downgrade

August 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT, BEAM, CRSP, and NTLA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.36 -0.49 (-2.91%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$16.56 +0.20 (+1.22%)

As of 08/29/2025 07:58 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$51.83 -1.22 (-2.30%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$51.80 -0.03 (-0.06%)

As of 08/29/2025 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Editas Medicine NASDAQ:EDIT

$2.57 -0.08 (-3.02%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.02 (-0.97%)

As of 08/29/2025 06:59 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$11.35 -0.25 (-2.16%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$11.40 +0.05 (+0.44%)

As of 08/29/2025 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time